- Home
- Medical news & Guidelines
- Anesthesiology
- Cardiology and CTVS
- Critical Care
- Dentistry
- Dermatology
- Diabetes and Endocrinology
- ENT
- Gastroenterology
- Medicine
- Nephrology
- Neurology
- Obstretics-Gynaecology
- Oncology
- Ophthalmology
- Orthopaedics
- Pediatrics-Neonatology
- Psychiatry
- Pulmonology
- Radiology
- Surgery
- Urology
- Laboratory Medicine
- Diet
- Nursing
- Paramedical
- Physiotherapy
- Health news
- Fact Check
- Bone Health Fact Check
- Brain Health Fact Check
- Cancer Related Fact Check
- Child Care Fact Check
- Dental and oral health fact check
- Diabetes and metabolic health fact check
- Diet and Nutrition Fact Check
- Eye and ENT Care Fact Check
- Fitness fact check
- Gut health fact check
- Heart health fact check
- Kidney health fact check
- Medical education fact check
- Men's health fact check
- Respiratory fact check
- Skin and hair care fact check
- Vaccine and Immunization fact check
- Women's health fact check
- AYUSH
- State News
- Andaman and Nicobar Islands
- Andhra Pradesh
- Arunachal Pradesh
- Assam
- Bihar
- Chandigarh
- Chattisgarh
- Dadra and Nagar Haveli
- Daman and Diu
- Delhi
- Goa
- Gujarat
- Haryana
- Himachal Pradesh
- Jammu & Kashmir
- Jharkhand
- Karnataka
- Kerala
- Ladakh
- Lakshadweep
- Madhya Pradesh
- Maharashtra
- Manipur
- Meghalaya
- Mizoram
- Nagaland
- Odisha
- Puducherry
- Punjab
- Rajasthan
- Sikkim
- Tamil Nadu
- Telangana
- Tripura
- Uttar Pradesh
- Uttrakhand
- West Bengal
- Medical Education
- Industry
Covid19: 65.25 crore Covishield , 9.1 crore Covaxin doses received by Center till September 19
New Delhi: The Centre has received over 65.25 crore Covishield doses from Serum Institute of India and 9.1 crore doses of Covaxin from Bharat Biotech till September 19, according to official documents.
Serum Institute of India (SII) has supplied 20.29 lakh doses of Covishield to the Union Ministry of Health in September as committed in August by Prakash Kumar Singh, Director, Government and Regulatory Affairs at the Pune-based firm.
The SII has informed the government that it will be able to supply around 22 crore doses of Covishield in October. The Centre has announced resuming the export of surplus vaccines in the fourth quarter of this fiscal under the ''Vaccine Maitri'' programme to meet its commitment to the COVAX global pool, official sources said.
The Pune-based pharmaceutical company has enhanced its Covishield manufacturing capacity to more than 20 crore doses per month.
Singh has also assured the government that by December 31, the Pune-based firm will complete the supply of 66 crore doses of Covishield against the recent order and will touch supplies of more than 130 crore doses in the year 2021.
The cumulative doses administered in the country so far under the nationwide COVID-19 vaccination drive has exceeded 89 crore.
Union Health Minister Mansukh Mandaviya on September 20 announced that India will resume export of surplus COVID-19 vaccines in the fourth quarter of 2021 under the ''Vaccine Maitri'' programme and to meet its commitment to the COVAX global pool, but vaccinating its own citizens remains the topmost priority of the government.
About the expected production and supply trends in the coming months, the minister said the government will receive over 30 crore doses of COVID-19 vaccines in October and over 100 crore doses in the upcoming quarter from October-December.
Read also: CDSCO allows Serum Institute to enrol 7-11 year-olds in COVID vaccine trial
Ruchika Sharma joined Medical Dialogue as an Correspondent for the Business Section in 2019. She covers all the updates in the Pharmaceutical field, Policy, Insurance, Business Healthcare, Medical News, Health News, Pharma News, Healthcare and Investment. She has completed her B.Com from Delhi University and then pursued postgraduation in M.Com. She can be contacted at editorial@medicaldialogues.in Contact no. 011-43720751